Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer
Status:
Recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
This is a Phase 1, two part, study of patients with recurrent Head and Neck Cancer (HNC),
who in the opinion of their physician, cannot be satisfactorily treated with surgery,
radiation or platinum chemotherapy. Part I is a drug dose-escalation, fixed low fluency
light application study to determine the drug dose that can be safely given to saturate the
epidermal growth factor receptor (EGFR) at the tumor.
Part II is a light treatment dose-escalation, fixed drug dosing infusion study to determine
the optimal light application, in combination with the Part I drug dose, needed to achieve
clinical response with an acceptable safety profile.